賽生藥業(06600.HK)穩定價格期間結束
賽生藥業(06600.HK)公布,穩定價格操作人中國國際金融香港證券或代其行事的任何人士於穩定價格期間,超額分配國際發售合共1,739.75萬股股份,佔超額配售權獲行使前全球發售初步可供認購發售股份總數的15%。
而穩定價格操作人根據借股協議向GL Trade Investment L.P.借入合共1,739.75萬股股份,以補足國際發售的超額分配。並於穩定價格期間內以介乎每股股14.28-18.8元的價格接連在市場購入合1,739.75萬股股份,佔超額配售權獲行使前全球發售初步可供認購發售股份總數的15%。
聯席代表未於穩定價格期間內行使超額配售權,超額配售權已於2021年3月26日失效,概無股份已經或將會根據超額配售權發行。(el/k) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.